Moderna (MRNA) is back in focus after Merck and the biotech released detailed Phase 3 data for their personalized melanoma therapy, intismeran autogene, paired with KEYTRUDA, showing improved recurrence and metastasis outcomes versus KEYTRUDA alone.
That melanoma readout comes on a stock that already has strong momentum. Moderna’s 1-day share price return of 4.01% at a US$222.76 close builds on a 7-day share price gain of 11.32% and a 30-day rise of 15.68%. Its roughly tripling 90-day share price return and very large year-to-date share price move sit behind a roughly 7x 1-year total shareholder return, even though the 5-year total shareholder return shows a small overall decline.
Capitalize on the momentum around Moderna by scanning a hand-picked 36 healthcare AI stocks.Moderna now has a high profile pipeline story and a share price that has run hard in a short span. The real work is figuring out whether that momentum already more than reflects what investors know today.
Most Popular Narrative: 64% Overvalued
At a last close of $222.76 versus a most followed narrative fair value of $135.84, Moderna looks richly priced and tightly linked to ambitious revenue and margin assumptions. The question for anyone watching this rally is how much of the vaccine breadth, oncology promise, and rare disease optionality is already being paid for upfront.
The current valuation, including a market cap around US$70b and a forward P/S of 36.8x cited by some bearish brokers, implies Moderna’s cancer and rare disease franchises will achieve very broad adoption and significant long-duration revenue that critics argue is already priced into the share price.
See why 219 investors see Moderna as 64% overvalued.
Result: Fair Value of $135.84 (OVERVALUED)
Still, if Moderna turns its five approved vaccines into steadier respiratory revenue and intismeran gains wider melanoma uptake, today’s overvaluation case could look less secure.
Find out about the key risks to this Moderna narrative.
Next Steps
Seeing both excitement and caution around Moderna, you have enough public data to stress test the story yourself and not just follow the crowd. To weigh the upside against the issues on the table, start with the 1 key reward and 1 important warning sign.
Looking for more investment ideas beyond Moderna?
If Moderna has sharpened your interest, do not stop here. Broader opportunities often sit just outside the obvious headline stories investors focus on first.
- Target potential upside in quality businesses that screen as priced below their estimated worth through the 30 high quality undervalued stocks.
- Prioritise resilience by zeroing in on companies with strong finances using the list of solid balance sheet and fundamentals (23 results).
- Hunt for future standouts by scanning the 18 high quality undiscovered gems before the wider market pays attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com